BACKGROUND: The variant polymorphism in the gene MDM2, SNP309, leads to increased level of mdm2 protein and subsequent downregulation of p53 tumor suppressor pathway. Presence of this single nucleotide polymorphism (SNP) has been associated with earlier tumorigenesis in patients with Li-Fraumeni syndrome, as well as decreased survival in patients with CLL. In addition, cells homozygous (G/G) for SNP 309 were found to have 10-fold increase resistance to topoisomerase II inhibitors in vitro. PROCEDURE: We genotyped children (n = 575) with de novo acute myeloid leukemia (AML) treated on three Children's Oncology Group protocols (CCG 2941/2961/AAML 03P1) for the presence of SNP309. Healthy blood donors were genotyped as control population. RESULTS: The variant G/G genotype was associated with an increased susceptibility to AML (OR 1.5; P = 0.049). However, the presence of the variant allele at SNP309 did not modify disease response or toxicity in children treated on CCG protocols 2941/2961. CONCLUSIONS: The variant SNP 309 influences susceptibility to pediatric AML, but does not impact overall response to therapy. (c) 2010 Wiley-Liss, Inc.
BACKGROUND: The variant polymorphism in the gene MDM2, SNP309, leads to increased level of mdm2 protein and subsequent downregulation of p53tumor suppressor pathway. Presence of this single nucleotide polymorphism (SNP) has been associated with earlier tumorigenesis in patients with Li-Fraumeni syndrome, as well as decreased survival in patients with CLL. In addition, cells homozygous (G/G) for SNP 309 were found to have 10-fold increase resistance to topoisomerase II inhibitors in vitro. PROCEDURE: We genotyped children (n = 575) with de novo acute myeloid leukemia (AML) treated on three Children's Oncology Group protocols (CCG 2941/2961/AAML 03P1) for the presence of SNP309. Healthy blood donors were genotyped as control population. RESULTS: The variant G/G genotype was associated with an increased susceptibility to AML (OR 1.5; P = 0.049). However, the presence of the variant allele at SNP309 did not modify disease response or toxicity in children treated on CCG protocols 2941/2961. CONCLUSIONS: The variant SNP 309 influences susceptibility to pediatric AML, but does not impact overall response to therapy. (c) 2010 Wiley-Liss, Inc.
Authors: Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo Journal: Blood Date: 2007-11-13 Impact factor: 22.113
Authors: Sara Cattelani; Raffaella Defferrari; Sonia Marsilio; Rita Bussolari; Olivia Candini; Francesca Corradini; Giovanna Ferrari-Amorotti; Clara Guerzoni; Luisa Pecorari; Chiara Menin; Roberta Bertorelle; Pierluigi Altavista; Heather P McDowell; Renata Boldrini; Carlo Dominici; Gian Paolo Tonini; Giuseppe Raschellà; Bruno Calabretta Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Irina Gryshchenko; Sebastian Hofbauer; Markus Stoecher; Peter T Daniel; Michael Steurer; Alexander Gaiger; Karin Eigenberger; Richard Greil; Inge Tinhofer Journal: J Clin Oncol Date: 2008-05-10 Impact factor: 44.544
Authors: Rebecca Suk Heist; Wei Zhou; Lucian R Chirieac; Thea Cogan-Drew; Geoffrey Liu; Li Su; Donna Neuberg; Thomas J Lynch; John C Wain; David C Christiani Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Kofi Asomaning; Amy E Reid; Wei Zhou; Rebecca S Heist; Rihong Zhai; Li Su; Eunice L Kwak; Lawrence Blaszkowsky; Andrew X Zhu; David P Ryan; David C Christiani; Geoffrey Liu Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531
Authors: Helena S Thurow; Fernando P Hartwig; Clarice S Alho; Deborah S B S Silva; Rafael Roesler; Ana Lucia Abujamra; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Bernardo L Horta; Odir A Dellagostin; Tiago Collares; Fabiana K Seixas Journal: Mol Biol Rep Date: 2013-05-10 Impact factor: 2.316